Navigation Links
Drug May Aid People With Advanced Thyroid Cancer
Date:8/14/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, Aug. 13 (HealthDay News) -- A new study shows that the chemotherapy drug vandetanib (Caprelsa) may extend life a bit for some thyroid cancer patients.

The results of phase 2 trials showed that patients taking the drug lived for 11 months without the cancer progressing, compared with six months for those receiving a placebo.

"This study is confirmation that vandetanib is effective in advanced thyroid cancer patients, not only in terms of overall response, but also in terms of progression-free survival," said lead researcher Dr. Martin Schlumberger, of the Institute Gustave Roussy in Villejuif, France. "Vandetanib should be used as first-line treatment in patients with progressive, untreatable thyroid cancer."

The report was published online Aug. 13 in the journal The Lancet Oncology.

For the study, Schlumberger's team randomly assigned 145 patients with late-stage thyroid cancer either to vandetanib or a placebo.

In addition to a longer period when the cancer didn't progress, patients taking vandetanib had their disease better controlled, with more patients having a complete or partial response to the drug, the researchers found.

Among patients taking the drug, 72 percent had disease progression, compared with 84 percent taking placebo.

Neither those taking vandetanib or placebo, however, showed better overall survival, the researchers noted. Among those taking vandetanib, 26 percent died; 29 percent of those taking a placebo died.

Patients with papillary thyroid cancer -- the most common type of thyroid cancer -- taking vandetanib had progression-free disease for an average of 16 months, compared with patients with rarer forms of cancer, where progression-free disease lasted an average of almost eight months.

Patients taking vandetanib had greater side effects, including abnormal heart rhythms (which can be deadly), diarrhea, weakness and fatigue. Two patients taking vandetanib died from the treatment, the researchers noted.

Vandetanib works by targeting three proteins known to play a role in the growth and spread of thyroid cancer.

For people without health insurance, a month's supply of vandetanib can cost more than $17,800, according to the American Society of Clinical Oncology. For those with insurance, co-pays vary by plan.

If caught early, thyroid cancer is often curable. "Typically, we talk about thyroid cancer being the great cancer," said Dr. Dennis Kraus, director of the Center for Head & Neck Oncology at Lenox Hill Hospital in New York City. "If you've got to have a cancer, this is the one."

In most cases, the risk of dying from thyroid cancer is 1 percent, Kraus noted. Treating the disease usually involves surgically removing the thyroid and the lymph nodes if they are involved. In addition, patients can receive radioactive iodine.

"It's only the minority of patients who ... develop recurrent disease or metastatic or locally advanced cancer, who go on to die of their disease," Kraus said.

With vandetanib, these types of patients may have improved survival, Kraus said.

"It's not a panacea," he said. "But in a group in which we thought we had no viable treatment, we now have something we can try to treat people with and either control their disease or prolong their survival."

More information

For more on thyroid cancer, visit the U.S. National Library of Medicine.

SOURCES: Martin Schlumberger, Institut Gustave Roussy, Villejeuf, France; Dennis Kraus, M.D., director, Center for Head & Neck Oncology, New York Head & Neck Institute, Lenox Hill Hospital, New York City; Aug. 13, 2012, The Lancet Oncology, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
2. Anxiety Might Help People Sniff Out Threats
3. People Carrying Guns May Appear Bigger Than They Are
4. CT Scans Deliver More Radiation to Obese People: Study
5. Good intentions bring mixed results for Haitis disabled people
6. Migraines More Likely for People With Celiac Disease, Study Says
7. People Love Talking About Themselves, Brain Scans Show
8. Older People With Dementia Cared for Mostly at Home
9. People With HIV at Higher Odds of Sudden Cardiac Death
10. People Who Lived Near World Trade Center Report More Lung Disease
11. 1 size doesnt fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug May Aid People With Advanced Thyroid Cancer
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... insight into the challenges employers face in trying to balance both short-term and ... benefits programs? Adding to the growing complexity, companies are finding that the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based ... industry. The organization, which plans to publish the first ANSI-approved GMP standard ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
(Date:3/29/2017)... 2017 Research and Markets has announced the addition ... Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... in 2016. There are currently three proton therapy centers in ... patients. In Italy , the first patients were treated ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... Policy, Patients Treated at Proton Therapy Centers & Forecast" report to ... The South ... its current market size in 2016. The Untapped Proton Therapy Market for ... Billion USD in 2016. Proton Therapy plays an important ...
Breaking Medicine Technology: